Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 6/20 | 0.36 |
| ▸ | NPC1 | O15118 | 3/20 | 0.36 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL795825 | 0.93 | ALDH1A1 (0.39) | NPC1RAB9ASMN1; SMN2LMNATSHR | |
| SCHEMBL795739 | 0.85 | S1PR1 (0.44) | S1PR1NPC1RAB9AS1PR3ACHE | |
| SCHEMBL797319 | 0.84 | ALOX5AP (0.43) | S1PR1NPC1RAB9AUSP2LMNA | |
| SCHEMBL10287193 | 0.82 | S1PR1 (0.33) | S1PR1ACHEL3MBTL1 | |
| SCHEMBL796120 | 0.82 | HDAC8 (0.40) | — | |
| SCHEMBL797145 | 0.82 | TP53 (0.36) | S1PR1NPC1RAB9AACHESMN1; SMN2 | |
| SCHEMBL10286911 | 0.81 | NPC1 (0.33) | S1PR1NPC1RAB9AL3MBTL1USP2 | |
| SCHEMBL10286922 | 0.81 | S1PR1 (0.33) | S1PR1S1PR3ACHE | |
| SCHEMBL796391 | 0.81 | DHFR (0.38) | NPC1RAB9AACHESMN1; SMN2LMNA | |
| SCHEMBL796202 | 0.81 | SCN9A (0.37) | S1PR1NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2616465-B1 | TRIAZINE-OXADIAZOLES | NOVARTIS AG (CH) | 2015-11-04 | — | — | EP | disclosed |
| EP-2616465-B1 | TRIAZINE-OXADIAZOLES | NOVARTIS AG (CH) | 2015-11-04 | — | — | EP | disclosed |
| US-20150025057-A1 | Triazine-oxadiazoles | NOVARTIS AG (CH) | 2015-01-22 | — | — | US | disclosed |
| US-20150025057-A1 | Triazine-oxadiazoles | NOVARTIS AG (CH) | 2015-01-22 | — | — | US | disclosed |
| US-20150025057-A1 | Triazine-oxadiazoles | NOVARTIS AG (CH) | 2015-01-22 | — | — | US | disclosed |
| US-8895733-B2 | Triazine-oxadiazoles | NOVARTIS AG (CH) | 2014-11-25 | — | — | US | disclosed |
| US-8895733-B2 | Triazine-oxadiazoles | NOVARTIS AG (CH) | 2014-11-25 | — | — | US | disclosed |
| US-8895733-B2 | Triazine-oxadiazoles | NOVARTIS AG (CH) | 2014-11-25 | — | — | US | disclosed |
| US-20140051676-A1 | Triazine-oxadiazoles | NOVARTIS AG (CH) | 2014-02-20 | — | — | US | disclosed |
| US-20140051676-A1 | Triazine-oxadiazoles | NOVARTIS AG (CH) | 2014-02-20 | — | — | US | disclosed |
| US-20140051676-A1 | Triazine-oxadiazoles | NOVARTIS AG (CH) | 2014-02-20 | — | — | US | disclosed |
| EP-2616465-A1 | TRIAZINE-OXADIAZOLES | Novartis AG (CH) | 2013-07-24 | — | — | EP | disclosed |
| WO-2012035023-A1 | TRIAZINE-OXADIAZOLES | NOVARTIS AG (CH) | 2012-03-22 | — | — | WO | disclosed |
| WO-2012035023-A1 | TRIAZINE-OXADIAZOLES | NOVARTIS AG (CH) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025057-A1 | Triazine-oxadiazoles | OPRK1, OPRD1, OPRL1 | S1PR1 2345/4885NPC1 3204/4885RAB9A 4766/4885 |
| US-20140051676-A1 | Triazine-oxadiazoles | OPRK1, OPRD1, OPRL1 | S1PR1 2345/4885NPC1 3204/4885RAB9A 4766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.